Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacira names senior VP, strategy

This article was originally published in Scrip

Executive Summary

Parsippany, New Jersey-based Pacira Pharmaceuticals has named Dr Scott Braunstein to the newly created position of senior vice-president of strategy and corporate development. Dr Braunstein brings over 20 years of knowledge and experience from his time both as a practising physician and investor, as well as expertise from numerous commercial, consulting and operational roles advising on strategy and organizational objectives for biotechnology and pharmaceutical companies. He will be responsible for evaluating, integrating and optimizing the company's strategic opportunities for the lead commercial product Exparel (bupivacaine liposome injectable suspension); the company's hospital-based sales franchise; the DepoFoam-based internal pipeline product candidates; and external in-licensing and acquisition product candidates. Before joining Pacira, Dr Braunstein was at Everpoint Asset Management.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029263

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel